BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children. METHODS: A total of 641 patients with de novo ALL who were treated with the hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen or its variants were analyzed. RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients). At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients. Frontline therapy included hyper-CVAD in 7 patients, hyper-CVAD with rituximab in 8 patients, and hyper-CVAD with imatinib in 1 patient. Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients. Secondary AML/MDS developed at a median of 32 months after ALL diagnosis. Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS. One patient with MDS received arsenic trioxide, 1 received clofarabine, and 2 received decitabine. Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated. Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation. The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months). CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor. Copyright (c) 2008 American Cancer Society.
BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children. METHODS: A total of 641 patients with de novo ALL who were treated with the hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen or its variants were analyzed. RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients). At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients. Frontline therapy included hyper-CVAD in 7 patients, hyper-CVAD with rituximab in 8 patients, and hyper-CVAD with imatinib in 1 patient. Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients. Secondary AML/MDS developed at a median of 32 months after ALL diagnosis. Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS. One patient with MDS received arsenic trioxide, 1 received clofarabine, and 2 received decitabine. Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated. Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation. The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months). CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor. Copyright (c) 2008 American Cancer Society.
Authors: C H Pui; F G Behm; S C Raimondi; R K Dodge; S L George; G K Rivera; J Mirro; D K Kalwinsky; G V Dahl; S B Murphy Journal: N Engl J Med Date: 1989-07-20 Impact factor: 91.245
Authors: Nobuko Hijiya; Melissa M Hudson; Shelly Lensing; Margie Zacher; Mihaela Onciu; Fred G Behm; Bassem I Razzouk; Raul C Ribeiro; Jeffrey E Rubnitz; John T Sandlund; Gaston K Rivera; William E Evans; Mary V Relling; Ching-Hon Pui Journal: JAMA Date: 2007-03-21 Impact factor: 56.272
Authors: Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich Journal: Cancer Date: 2004-12-15 Impact factor: 6.860
Authors: Dawn Hershman; Alfred I Neugut; Judith S Jacobson; Jian Wang; Wei-Yann Tsai; Russell McBride; Charles L Bennett; Victor R Grann Journal: J Natl Cancer Inst Date: 2007-02-07 Impact factor: 13.506
Authors: Saar Gill; Steven W Lane; Julie Crawford; Gavin Cull; David Joske; Paula Marlton; Peter N Mollee; H Miles Prince; John F Seymour Journal: Ann Hematol Date: 2008-04-10 Impact factor: 3.673
Authors: C H Pui; R C Ribeiro; M L Hancock; G K Rivera; W E Evans; S C Raimondi; D R Head; F G Behm; M H Mahmoud; J T Sandlund Journal: N Engl J Med Date: 1991-12-12 Impact factor: 91.245
Authors: N J Winick; R W McKenna; J J Shuster; N R Schneider; M J Borowitz; W P Bowman; D Jacaruso; B A Kamen; G R Buchanan Journal: J Clin Oncol Date: 1993-02 Impact factor: 44.544
Authors: Gerd Birkenmeier; Nasr Y A Hemdan; Susanne Kurz; Marina Bigl; Philipp Pieroh; Tewodros Debebe; Martin Buchold; Rene Thieme; Gunnar Wichmann; Faramarz Dehghani Journal: PLoS One Date: 2016-08-31 Impact factor: 3.240